|
2015 Journal Article A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health servicesBeesley, Vanessa L., Janda, Monika, Goldstein, David, Gooden, Helen, Merrett, Neil D., O'Connell, Dianne L., Rowlands, Ingrid J., Wyld, David and Neale, Rachel E. (2015). A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. Psycho-Oncology, 25 (2), 150-157. doi: 10.1002/pon.3887 |
|
2015 Journal Article Describing patterns of care in pancreatic cancer a population-based studyBurmeister, Elizabeth A., O'Connell, Dianne L., Beesley, Vanessa L., Goldstein, David, Gooden, Helen M., Janda, Monika, Jordan, Susan J., Merrett, Neil D., Payne, Madeleine E., Wyld, David and Neale, Rachel E. (2015). Describing patterns of care in pancreatic cancer a population-based study. Pancreas, 44 (8), 1259-1265. doi: 10.1097/MPA.0000000000000384 |
|
2014 Journal Article Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysisBeesley, Vanessa L., Green, Adele C., Wyld, David K., O'Rourke, Peter, Wockner, Leesa F., Defazio, Anna, Butow, Phyllis N., Price, Melanie A., Horwood, Keith R., Clavarino, Alexandra M. and Webb, Penelope M. (2014). Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis. Obstetrical and Gynecological Survey, 69 (5), 257-259. doi: 10.1097/01.ogx.0000450117.94530.01 |
|
2014 Journal Article Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysisBeesley, Vanessa L., Green, Adele C., Wyld, David K., O'Rourke, Peter, Wockner, Leesa F., deFazio, Anna, Butow, Phyliss N., Price, Melanie A., Horwood, Keith R., Clavarino, Alexandra M., Australian Ovarian Cancer Study Group, Australian Ovarian Cancer Study - Quality of Life Study Investigators and Webb, Penelope M. (2014). Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis. Gynecologic Oncology, 132 (1), 130-136. doi: 10.1016/j.ygyno.2013.10.004 |
|
2013 Journal Article The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimatesKiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas R. C., Wyld, David K., Abdi, Ehtesham A., Glasgow, Amanda, Beale, Philip J., Jefford, Michael, Glare, Paul A. and Stockler, Martin R. (2013). The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. Journal of Clinical Oncology, 31 (28), 3565-3572. doi: 10.1200/JCO.2012.44.7821 |
|
2013 Journal Article Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based studyJordan, S., Steer, C., DeFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D. and Webb, P. (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study. Gynecologic Oncology, 129 (2), 310-317. doi: 10.1016/j.ygyno.2013.02.007 |
|
2012 Journal Article Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trialNeoptolemos, John P., Moore, Malcolm J., Cox, Trevor F., Valle, Juan W., Palmer, Daniel H., McDonald, Alexander C., Carter, Ross, Tebbutt, Niall C., Dervenis, Christos, Smith, David, Glimelius, Bengt, Charnley, Richard M., Lacaine, François, Scarfe, Andrew G., Middleton, Mark R., Anthoney, Alan, Ghaneh, Paula, Halloran, Christopher M., Lerch, Markus M., Oláh, Attila, Rawcliffe, Charlotte L., Verbeke, Caroline S., Campbell, Fiona, Büchler, Markus W., European Study Group for Pancreatic Cancer and Wyld, David (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308 (2), 147-56. doi: 10.1001/jama.2012.7352 |
|
2012 Journal Article Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2Kirchhoff, Tomas, Gaudet, Mia M., Antoniou, Antonis C., McGuffog, Lesley, Humphreys, Manjeet K., Dunning, Alison M., Bojesen, Stig E., Nordestgaard, Borge G., Flyger, Henrik, Kang, Daehee, Yoo, Keun-Young, Noh, Dong-Young, Ahn, Sei-Hyun, Dork, Thilo, Schuermann, Peter, Karstens, Johann H., Hillemanns, Peter, Couch, Fergus J., Olson, Janet, Vachon, Celine, Wang, Xianshu, Cox, Angela, Brock, Ian, Elliott, Graeme, Reed, Malcolm W. R., Burwinkel, Barbara, Meindl, Alfons, Brauch, Hiltrud, Hamann, Ute ... Wyld, David (2012). Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. Plos One, 7 (6) e35706, e35706-1-e35706-10. doi: 10.1371/journal.pone.0035706 |
|
2012 Journal Article The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopauseChirgwin, Jacquie, Sun, Zhuoxin, Smith, Ian, Price, Karen N., Thuerlimann, Beat, Ejlertsen, Bent, Bonnefoi, Herve, Regan, Meredith M., Goldhirsch, Aron, Coates, Alan S., International Breast Cancer Study Group (IBCSG) and Wyld, David (2012). The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Research and Treatment, 131 (1), 295-306. doi: 10.1007/s10549-011-1741-6 |
|
2011 Journal Article Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyPavel, Marianne E., Hainsworth, John D., Baudin, Eric, Peeters, Marc, Hörsch, Dieter, Winkler, Robert E., Klimovsky, Judith, Lebwohl, David, Jehl, Valentine, Wolin, Edward M., Öberg, Kjell, Van Cutsem, Eric, Yao, James C., RADIANT-2 Study Group and Wyld, D. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. The Lancet, 378 (9808), 2005-2012. doi: 10.1016/S0140-6736(11)61742-X |
|
2011 Journal Article Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot studyNewton, Melissa J ., Hayes, Sandi C., Janda, Monika, Webb, Penelope M., Obermair, Andreas, Eakin, Elizabeth G., Wyld, David, Gordon, Louisa G. and Beesley, Vanessa L. (2011). Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study. BMC Cancer, 11 (1) 389, 389-1-389-9. doi: 10.1186/1471-2407-11-389 |
|
2011 Journal Article Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancerRegan, Meredith M, Price, Karen N, Giobbie-Hurder, Anita, Thürlimann, Beat, Gelber, Richard D, International Breast Cancer Study Group and BIG 1-98 Collaborative Group, Colosimo, M., Cheuk, R., Kenny, L., McCarthy, N. and Wyld, D. (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast cancer research : BCR, 13 (3) 209, 209. doi: 10.1186/bcr2837 |
|
2011 Journal Article Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinomaObermair, Andreas, Mileshkin, Linda, Bolz, Katharina, Kondalsamy-Chennakesavan, Srinivas, Cheuk, Robyn, Vasey, Paul, Wyld, David, Goh, Jeffrey, Nicklin, James L., Perrin, Lewis C., Sykes, Peter and Janda, Monika (2011). Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. Gynecologic Oncology, 120 (2), 179-184. doi: 10.1016/j.ygyno.2010.10.039 |
|
2010 Journal Article Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agentLickliter, J. D., Francesconi, A. B., Smith, G., Burge, M., Coulthard, A., Rose, S., Griffin, M., Milne, R., McCarron, J., Yeadon, T., Wilks, A., Cubitt, A., Wyld, D. K. and Vasey, P. A. (2010). Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 103 (5), 597-606. doi: 10.1038/sj.bjc.6605841 |
|
2010 Journal Article Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patientsBeesley, Vanessa L., Clavarino, Alexandra M., Webb, Penelope M., Wyld, David K., Francesconi, Alessandra B., Horwood, Keith R., Doecke, James D., Loos, Colleen A. and Green, Adele C. (2010). Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Supportive Care in Cancer, 18 (8), 943-949. doi: 10.1007/s00520-009-0734-z |
|
2010 Journal Article Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 yearsGordon, Louisa G., Scuffham, Paul A., Beesley, Vanessa L., Green, Adele C., DeFazio, Anna, Wyld, David K., Clavarino, Alexandra M., Australian Ovarian Cancer Study Group and Webb, Penelope M. (2010). Medical costs and outcomes for Australian women with ovarian cancer: A patient-level analysis over 2.5 years. International Journal of Gynecological Cancer, 20 (5), 757-765. doi: 10.1111/IGC.0b013e3181dbd13f |
|
2010 Journal Article Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX studyTebbutt, Niall C., Wilson, Kate, Gebski, Val J., Cummins, Michelle M., Zannino, Diana, Van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P., Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Price, Tim, Simes, John, Coates, Alan, O'Connell, Diane, Brown, Chris, Hague, Wendy, France, Alyson, Hicks, Sian, James, Rebecca, Masson, Ruby, O'Connell, Rachel ... Gebbie, Chantal (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. Journal of Clinical Oncology, 28 (19), 3191-3198. doi: 10.1200/JCO.2009.27.7723 |
|
2010 Journal Article Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiformeFrancesconi, Alessandra B., Dupre, Simon, Matos, Marco, Martin, David, Hughes, Brett G., Wyld, David K. and Lickliter, Jason D. (2010). Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience, 17 (8), 970-974. doi: 10.1016/j.jocn.2009.12.009 |
|
2009 Journal Article Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancersHerbertson, Rebecca A., Tebbutt, Niall C., Lee, Fook-Thean, MacFarlane, David J., Chappell, Bridget, Micallef, Noel, Lee, Sze-Ting, Saunder, Timothy, Hopkins, Wendie, Smyth, Fiona E., Wyld, David K., Bellen, John, Sonnichsen, Daryl S., Brechbiel, Martin W., Murone, Carmel and Scott, Andrew M. (2009). Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clinical Cancer Research, 15 (21), 6709-6715. doi: 10.1158/1078-0432.CCR-09-0536 |
|
2009 Journal Article Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 TrialAu, Heather-Jane, Karapetis, Christos S., O'Callaghan, Chris J., Tu, Dongsheng, Moore, Malcolm J., Zalcberg, John R., Kennecke, Hagen, Shapiro, Jeremy D., Koski, Sheryl, Pavlakis, Nick, Charpentier, Danielle, Wyld, David, Jefford, Michael, Knight, Gregory J., Magoski, Nadine M., Brundage, Michael D. and Jonker, Derek J. (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27 (11), 1822-1828. doi: 10.1200/JCO.2008.19.6048 |
